Evidence map›Paper›PMID 36533661›Full record

ArticleMolecular pharmaceutics2023

Hierarchical Macro-Mesoporous Silica Monolithic Tablets as a Novel Dose-Structure-Dependent Delivery System for the Release of Confined Dexketoprofen.

Marta Kozakiewicz-Latała, Dominik Marciniak, Karolina Krajewska, Adrianna Złocińska, Krystian Prusik, Bożena Karolewicz, Karol P Nartowski, Wojciech Pudło

Abstract read
In one paragraph

Article in Molecular pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Marta Kozakiewicz-LatałaDepartment of Drug Forms Technology, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211, Wroclaw50-556, Poland.
Dominik MarciniakDepartment of Drug Forms Technology, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211, Wroclaw50-556, Poland.
Karolina KrajewskaDepartment of Drug Forms Technology, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211, Wroclaw50-556, Poland.
Adrianna ZłocińskaLaboratory of Elemental Analysis Structural Research, Wroclaw Medical University, Borowska 211, Wroclaw50-556, Poland.
Krystian PrusikInstitute of Materials Engineering, University of Silesia in Katowice, 75 Pulku Piechoty 1A, Chorzow40-007, Poland.
Bożena KarolewiczDepartment of Drug Forms Technology, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211, Wroclaw50-556, Poland.
Karol P NartowskiDepartment of Drug Forms Technology, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211, Wroclaw50-556, Poland.ORCID 0000-0003-1915-5195
Wojciech PudłoDepartment of Chemical Engineering and Process Design, Silesian University of Technology, Gliwice44-100, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study reports the application of hierarchical porous monoliths as carriers for controlled and dose-adjustable release of model pharmaceutical (dexketoprofen, DEX). The synthesis and detailed characterization of the hierarchical porous scaffolds are provided before and after the adsorption of three doses of DEX─a widely used nonsteroidal anti-inflammatory drug. The drug incorporated in the mesopores of silica was stabilized in an amorphous state, while the presence of macropores provided sufficient space for drug crystallization as we demonstrated via a combination of powder X-ray diffraction, differential scanning calorimetry, and imaging techniques (scanning electron microscopy and EDX analysis). Drug release from silica matrices was tested, and a mechanistic model of this release based on the Fick diffusion equation was proposed. The hierarchical structure of the carrier, due to the presence of micrometric macropores and nanometric mesopores, turned out to be critical for the control of the drug phase and drug release from the monoliths. It was found that at low drug content, the presence of an amorphous component in the pores promoted the rapid release of the drug, while at higher drug contents, the presence of macropores favored the crystallization of DEX, which naturally slowed down its release. Both the hierarchical porous structure and the control of the drug phase (amorphous and/or crystalline) were proven important for adjustable (fast or prolonged) release kinetics, desirable for effective pharmacotherapy and patient compliance. Therefore, the developed materials may serve as a versatile formulation platform for the smart manipulation of drug release kinetics.

Indexed as

Drug CarriersSilicon DioxideCalorimetry, Differential ScanningDrug LiberationHumansKetoprofenPorositySolubilityTabletsTromethamineX-Ray Diffractiondexketoprofen trometamolDrug CarriersKetoprofenSilicon DioxideTabletsTromethaminecontrolled and adjustable release of dexketoprofendexketoprofen crystallization in macroporous structureshierarchical porous drug carriersmacropore-favored crystallizationsilica monolithic tablets

Identifiers

PMID36533661
PMCPMC9811460

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.